BRCA1 and BRCA2 Mutations: Should You Get Tested and What Do Results Mean?

Imagine being told you carry a BRCA1 or BRCA2 mutation. Your lifetime risk of breast cancer is 45 to 87 percent. Your lifetime risk of ovarian cancer is 25 to 50 percent. Multiple family members died of cancer before age 50. Yet this knowledge—though initially terrifying—enables informed decision-making. You can choose surveillance strategies. Enhanced screening. Preventive medications. Preventive surgery. You gain agency. You take control. The same mutation that devastated your family now empowers you to make informed choices that dramatically reduce your cancer risk. BRCA1 and BRCA2 mutations represent one of the most significant cancer predisposition syndromes. Understanding the genetic basis, cancer risk, testing approaches, and prevention strategies enables individuals and families to make informed decisions about health management and family planning. BRCA1 and BRCA2 are tumor suppressor genes. Mutations impair DNA damage response and cell cycle control. Loss of function increases cancer risk—particularly breast and ovarian cancer. Women with mutations have 45 to 87 percent lifetime breast cancer risk. 25 to 50 percent lifetime ovarian cancer risk. Men with mutations have increased prostate and breast cancer risk. BRCA mutations affect approximately 1 in 400 to 1 in 800 people in general population. Higher in Ashkenazi Jewish population. Approximately 1 in 40. BRCA mutations account for approximately 5 to 10 percent of breast cancers. Approximately 10 to 15 percent of ovarian cancers. What makes BRCA mutations important is the dramatic cancer risk yet the significant potential for risk reduction through screening, prevention, and early detection. Testing enables informed decision-making. Risk reduction strategies dramatically reduce cancer incidence. Early detection improves survival. Understanding BRCA mutations helps individuals and families reduce cancer burden. In this comprehensive article, we will explore what BRCA1 and BRCA2 genes are, understand mutation effects, recognize who should get tested, interpret test results, explore cancer risks, and discover prevention and surveillance strategies enabling risk reduction.

Understanding BRCA Gene Function and BRCA Mutation Effects

Before we explore BRCA mutations, we need to understand BRCA gene function and how mutations increase cancer risk. BRCA1 gene. Located on chromosome 17. Encodes BRCA1 protein. Tumor suppressor. DNA repair. Homologous recombination repair. Recognizes DNA damage. Recruits repair machinery. Repairs double-strand breaks. Essential for maintaining genomic stability. Loss of BRCA1. DNA damage accumulation. Genomic instability. Cell cycle dysregulation. Apoptosis evasion. Cancer development. BRCA2 gene. Located on chromosome 13. Encodes BRCA2 protein. Tumor suppressor. DNA repair. Homologous recombination repair. Similar function to BRCA1. Different protein. Different mechanism. Essential for genomic stability. Loss of BRCA2. DNA damage accumulation. Genomic instability. Cancer development. BRCA protein functions. DNA damage recognition. Protein complexes. RAD51. Other proteins. DNA damage sensing. Activation of repair pathways. Cell cycle checkpoint control. G1/S checkpoint. DNA damage detected. Cell cycle arrested. Repair attempted. If repair fails. Apoptosis. Cell death. If repair succeeds. Cell cycle resumes. Apoptosis regulation. If damage too severe. Programmed cell death. Cancer prevention. Loss of function. If BRCA nonfunctional. DNA damage not repaired. Cell cycle checkpoint bypassed. Damaged cells divide. Genomic instability increases. Cancer development. Two-hit hypothesis. Germline mutation. One BRCA copy mutated. Inherited. All cells have one mutated copy. Somatic mutation. Second hit. Occurs in individual cell. That cell has both copies mutated. Loss of both BRCA proteins. DNA repair failure. Uncontrolled cell division. Tumor develops. Heterozygotes. One normal copy. Usually sufficient. But cancer risk increased. Homozygotes. Two mutated copies. Extremely high cancer risk. Usually not viable in embryos. Biallelic inactivation required for tumor formation. BRCA mutations. Over 3,000 known mutations. Different mutations. Different effects. Frameshift mutations. Nonsense mutations. Large deletions. Complete loss of function. Truncating mutations. Missense mutations. Variable function. Some functional. Some non-functional. Splice site mutations. Missense mutations. Variable severity. Genetic testing. DNA sequencing. Identifies specific mutation. Multigene panel testing. Tests multiple genes. Not just BRCA. Identifies associated genes. Increases detection. BRCA and cancer development. Age-related penetrance. Not all carriers develop cancer. Lifetime risk high. But not 100 percent. Ovarian cancer. 25 to 50 percent lifetime risk. Higher in BRCA1. Lower in BRCA2. Breast cancer. 45 to 87 percent lifetime risk. Higher in BRCA1. Slightly lower in BRCA2. Early onset. Cancer occurs younger. Often before age 50. Younger ages than sporadic cancer. Multiple primary cancers. Carriers can develop multiple cancers. Breast bilateral. Breast and ovarian. Other cancers. Prostate. Pancreatic. Colorectal. Male carriers. Breast cancer. BRCA2 particularly. Increased risk. Prostate cancer. BRCA1 and BRCA2. Increased risk. Pancreatic cancer. Both genes. Bile duct cancer. BRCA1. Other malignancies. Variable. The germline mutation significantly increases cancer risk across multiple cancer types.

What Are BRCA1 and BRCA2 Mutations?

BRCA1 and BRCA2 mutations are genetic variants in tumor suppressor genes that dramatically increase cancer risk, particularly breast and ovarian cancer. Gene mutations. Autosomal dominant inheritance. One mutated copy sufficient for cancer predisposition. Affected individual. 50 percent chance offspring inherits mutation. Heterozygous carriers. One normal, one mutated copy. Disease present. Cancer risk increased. Homozygous. Two mutated copies. Extremely high cancer risk. Rare. Usually embryonic lethal. De novo mutations. Spontaneous. Neither parent carrier. Can occur. Patient carries mutation. Offspring risk 50 percent. Inheritance patterns. Maternal or paternal transmission. No parent-of-origin effect. Both males and females. Both transmit equal risk. Genetic counseling. Inheritance discussion. Family planning implications. Mutation discovery. Genetic testing. DNA sequencing. Identifies specific mutation. Pathogenicity classification. Pathogenic mutations. Clearly increase cancer risk. Benign variants. No increased risk. Variants of uncertain significance (VUS). Unknown effect. Risk unclear. Requires further investigation. Novel mutations. New mutations. Function unknown. Interpretation difficult. Cancer risk from BRCA mutations. Breast cancer risk. BRCA1. 45 to 87 percent lifetime risk. Varies by mutation. Varies by population. Approximately 70 percent average. Women. BRCA2. Approximately 45 to 84 percent. Slightly lower than BRCA1. Men. BRCA1. 1 to 2 percent breast cancer risk. Very low. BRCA2. 5 to 7 percent breast cancer risk. Increased. Ovarian cancer risk. BRCA1. 25 to 50 percent lifetime risk. Approximately 40 percent average. BRCA2. 10 to 25 percent lifetime risk. Approximately 15 percent average. Prostate cancer risk. BRCA1 and BRCA2. Increased risk. Approximately 30 to 40 percent lifetime. More in BRCA2 than BRCA1. Age of diagnosis. Young for prostate. Often before age 65. Pancreatic cancer risk. BRCA1. Approximately 1 to 5 percent lifetime. BRCA2. Approximately 2 to 7 percent lifetime. Small risk but elevated. Colorectal cancer risk. Increased. Approximately 1.5 to 3 times elevated. Relative risk. Bile duct cancer. BRCA1. Increased risk. Other cancers. Melanoma. Stomach. Liver. Other malignancies. Variable increased risk. Hormone influences. Estrogen. Reproductive factors. Pregnancy. Breastfeeding. Oral contraceptive use. Hormone replacement. Influence risk. Oral contraceptives. Reduce ovarian cancer risk. Increase breast cancer risk. Marginal. Complex. Pregnancy. Reduces ovarian cancer risk. Reduces lifetime breast cancer risk. Protective effect. Breastfeeding. Reduces breast and ovarian cancer risk. Hormone replacement therapy. Increases breast cancer risk. Should avoid. Modifiable factors. Alcohol. Increased consumption. Increased breast cancer risk. Obesity. Increased risk. After menopause. Smoking. Associated with increased lung cancer. Not clearly BRCA-specific. Physical activity. Reduces cancer risk. Healthy diet. Reduces cancer risk. Risk reduction. Cancer risk varies. Not absolute. Some carriers never develop cancer. Others develop young. Multiple primary cancers. Genetic heterogeneity. Different mutations. Different risks. Mutation location. Type of mutation. C-terminal vs N-terminal BRCA1. Different associations. Different risks. Population-specific risks. Founder mutations. Specific mutations in populations. Different prevalence. Different penetrance. Ashkenazi Jewish population. Three founder mutations. BRCA1 5382insC. BRCA1 185delAG. BRCA2 6174delT. Increased prevalence. Approximately 1 in 40. Much higher than general population. The genetic basis explains the cancer predisposition and inheritance patterns.

Who Should Get Tested for BRCA Mutations?

Determining who should get BRCA testing requires assessment of personal and family history. Personal history. Breast cancer. Diagnosed before age 50. BRCA testing recommended. Any age. Jewish ancestry. Testing recommended. Male breast cancer. BRCA testing recommended. Very high risk. Ovarian cancer. At any age. BRCA testing recommended. Pancreatic cancer. Age before 60. Prostate cancer. Age before 65. High-grade disease. Family history. Breast cancer. Multiple family members. Two or more affected. Any age. Relative diagnosed before age 50. Ovarian cancer. Family member diagnosed. Any age. BRCA testing recommended. Male breast cancer. Family member affected. Ashkenazi Jewish ancestry. One or more cancer diagnoses. Any age. Prostate cancer. In relative. Colorectal cancer. In relative. Multiple primary cancers. Same relative. Testing guideline recommendations. National Cancer Institute. American Cancer Society. American Society of Breast Surgeons. ASCO. American Society of Clinical Oncology. Testing recommendations. Based on personal and family history. Genetic counseling. Prior to testing. Recommended. Discussion of. Mutation risk. Cancer risks if carrier. Implications. Psychological impact. Medical management options. Informed consent. Testing decisions. Screening recommendations. Surveillance options. Prevention options. Pros and cons. Medical management. Psychological support. Support for adverse results. Testing approach. Genetic counselor. Assesses risk. Discusses testing. Obtains consent. Phlebotomist. Draws blood. Laboratory testing. DNA sequencing. Results. 4 to 6 weeks. Usually. Genetic counselor. Results discussion. Implications. Next steps. Pre-test counseling. Before getting results. Healthcare provider. Discusses what results mean. Discusses medical management. Discusses prevention. Post-test counseling. After results available. Discussion of results. Implications. Medical management recommendations. Family member testing. Psychological support. Counseling needs. Relatives at risk. Discussion of. Risk to relatives. Implications. Recommendation for testing. Different hereditary cancer syndromes. BRCA1 and BRCA2. Most well-known. Lynch syndrome. HNPCC. MLH1. MSH2. MSH6. PMS2 mutations. Colorectal cancer. Endometrial cancer. Other cancers. PTEN. Cowden syndrome. P53. Li-Fraumeni syndrome. Multiple cancers. ATM. Familial pancreatic cancer. Multiple genes. Complex inheritance. Variable risks. Different management strategies. Multigene panel testing. Tests multiple genes. Not just BRCA. Identifies other hereditary cancer syndromes. Increases detection. Important. The complexity of hereditary cancer requires professional guidance.

Interpreting BRCA Test Results

Understanding BRCA test results and what they mean requires genetic counseling and medical guidance. Test result categories. Pathogenic mutation detected. Clearly increases cancer risk. Mutation associated with increased cancer risk. Established. Clear recommendation for medical management. Surveillance. Prevention. Screening. Medical counseling. Gene-specific recommendations. BRCA1 and BRCA2. Different recommendations. Different cancer risks. Different prevention options. Benign variant detected. Does not increase cancer risk. Does not require medical management. No cancer screening changes needed. Family member testing. Not indicated. Results summary. No increased cancer risk from this variant. Testing reassurance. Negative result. No BRCA1 or BRCA2 mutation detected. No increased cancer risk. OR. Residual risk. Undetected BRCA mutation. 5 to 10 percent chance. Other hereditary genes. Lynch. PTEN. ATM. Others. Family history assessment. If strong history. Despite negative BRCA. May warrant. Other testing. Risk assessment discussion. Cancer risk. If no BRCA mutation. Population risk. Screening recommendations. Standard population recommendations. Mammography age 40 to 50. Annual or biennial. Colonoscopy. Age 50. Every 10 years. Other cancer screening. General recommendations. Variant of uncertain significance (VUS). Unknown effect. Function unclear. Classified as VUS. Not pathogenic established. Not benign established. Requires further research. Management recommendations. Similar to BRCA-negative. Until function clarified. Reclassification possible. As more research. Information accumulates. Recontact. If reclassification occurs. Updates provided. Research participation. May contribute. Understanding of variant. Novel mutations. New mutations. Never reported. Function unknown. Usually classified as VUS. Sometimes. Pathogenic assumed. If truncating. If located in critical region. Risk counseling important. Research participation. Contributing to understanding. Genetic heterogeneity. Test coverage. Standard panel. BRCA1 and BRCA2. Extended panel. Multiple genes. Comprehensive panel. 80 to 100 genes. Turnaround time. Results available. Usually 4 to 6 weeks. Rush testing. Available. More expensive. 1 to 2 weeks. Cost. Insurance coverage. Usually covered. If testing indicated. Out-of-pocket cost. If not covered. Testing companies. Provide information. Financial assistance. Available. Genetic discrimination. Legal protections. Genetic Information Nondiscrimination Act (GINA). Protects against discrimination. Employment. Health insurance. Does not cover. Life insurance. Long-term care insurance. Disability insurance. Privacy. Test results. Confidential. Protected by HIPAA. Access. Genetic counselor. Physician. Patient. Family member access. Generally requires. Consent or legal authority. Retest. If inconclusive. Reflex testing. Automatically performed. No additional cost. Confirmatory testing. Second test. If concerning. Different methodology. Confirmation of results. The complexity of interpreting results requires professional guidance.

Medical Management: Surveillance and Prevention Strategies

BRCA mutation carriers have multiple options for cancer risk reduction. Enhanced surveillance. Breast cancer screening. Mammography. Starting age 30 to 40. Annual. Magnetic resonance imaging (MRI). Starting age 30. Annual. MRI more sensitive. Detects more cancers. Supplemental. For dense breast tissue. For high-risk individuals. Clinical breast examination. Monthly self-exam. Professional exam. Annual or every 6 months. Ovarian cancer screening. Transvaginal ultrasound. Annual or every 6 months. Cancer antigen 125 (CA-125). Blood test. Annually or every 6 months. Screening efficacy. Limited. May detect advanced cancer. Does not prevent. Does not prevent cancer. Early detection. Improves survival. But screening results. Inconclusive often. Unnecessary testing. Anxiety. Discussion of screening benefit and limitations. Important. Decision-making. Individual. Prostate cancer screening. PSA testing. Age 40 to 50 onwards. Annual. Digital rectal exam. Professional counseling. Benefits and harms. Risk assessment. Pancreatic cancer screening. Not routine. No standard screening. Surveillance MRI or CT. If family history. Multiple relatives. Early-onset pancreatic cancer. High-risk centers. Research protocols. Colorectal cancer screening. Standard colonoscopy. Age 40 to 50. Every 5 to 10 years. Earlier if family history. Preventive medications. Tamoxifen. Selective estrogen receptor modulator (SERM). Reduces breast cancer risk. 35 to 50 percent reduction. BRCA1 and BRCA2 carriers. Breast cancer prevention. Side effects. Hot flashes. Thromboembolic events. Vaginal discharge. Others. Tolerance variable. Raloxifene. SERM. Similar to tamoxifen. Slightly less effective. Similar side effects. Aromatase inhibitors. Letrozole. Anastrozole. Exemestane. Reduce breast cancer risk. More effective. Fewer thromboembolic events. More bone loss. Postmenopausal women primarily. Aspirin. Daily low-dose. Reduces cancer risk. Colorectal. Others. Risk reduction. Small. Generally well-tolerated. Oophorectomy. Ovarian cancer risk reduction. Bilateral salpingo-oophorectomy (BSO). Surgical removal. Ovaries and fallopian tubes. Definitive. 95 to 100 percent ovarian cancer risk reduction. Approximately 50 percent breast cancer risk reduction. Age at oophorectomy. Optimal age. Before 40. Preferred. Reduces breast cancer. Does not eliminate. Surgical menopause. Hot flashes. Vaginal dryness. Mood changes. Osteoporosis risk. Hormone replacement therapy. For menopausal symptoms. Increases breast cancer risk. Careful decision-making. Benefits and risks. Non-hormonal alternatives. Cognitive behavioral therapy. Antidepressants. Others. Preventive mastectomy. Risk-reducing mastectomy. Prophylactic mastectomy. Surgical removal. Breast tissue. Not cancer removed. Cancer prevention. NOT cancer treatment. Unaffected breast. Approximately 90 to 95 percent breast cancer risk reduction. Does not eliminate risk. Residual breast tissue. Not all breast tissue removed. Surgical menopause. Not induced. Ovaries remain. Breast reconstruction options. Silicone implants. Saline implants. Autologous tissue. Own tissue. Skin-sparing or nipple-sparing. Preserves appearance. Complications. Infection. Bleeding. Implant rupture. Revision surgery. Psychosocial impact. Body image. Sexual function. Emotional adjustment. Decision-making. Personal choice. Values. Preferences. Risk tolerance. Family discussion. Healthcare provider discussion. Genetic counselor discussion. Psychological assessment. Recommended. Multiple discussions. Reproductive counseling. Family planning. Offspring risk. If carrier. 50 percent. Prenatal diagnosis. Possible. Preimplantation genetic diagnosis (PGD). Genetic screening of embryos. IVF. Selects unaffected embryo. Enables pregnancy without mutation transmission. Adoption. Alternative. Genetic testing. Relatives. At-risk. Testing discussion. Risk assessment. Psychological support. Counseling. Adjustment to positive result. Cancer risk knowledge. Surveillance decisions. Prevention decisions. Support groups. Meeting others. Shared experiences. Coping strategies. Mental health. Screening for anxiety and depression. Treatment if indicated. Counseling. Psychotherapy. Medication. Support networks. Family. Friends. Medical team. Occupational impact. Work accommodation. If genetic counselor. If medical appointments. Frequent. Flexibility. Religious or spiritual guidance. Values-based decision-making. End-of-life planning. Advanced directives. Goals of care. Discussion if cancer develops. The comprehensive approach enables informed decision-making and risk reduction.

Frequently Asked Questions (FAQs)

Q1: If I have a BRCA mutation, will I definitely get cancer?

No, BRCA mutation does not guarantee cancer. High lifetime risk. But not 100 percent. Some carriers never develop cancer. Age. Cancer may develop. Late in life. After life expectancy. Luck. Some escape cancer. Others develop young. BRCA mutation—significant risk. But not certainty. Testing enables surveillance. Early detection. Prevention. Risk reduction. But not prevention of all cancer.

Q2: What should I do if I test positive for a BRCA mutation?

Work with genetic counselor. Discuss results. Discuss medical management options. Surveillance. Mammography. MRI. Transvaginal ultrasound. Prevention. Tamoxifen. Aromatase inhibitors. Oophorectomy. Mastectomy. Individual decision. Based on. Risk tolerance. Personal values. Family history. Life circumstances. Healthcare provider. Develops individualized plan. Genetic testing. Family members. Relatives at risk. Carrier identification. Early intervention. Psychological support. Counseling. Support groups. Regular medical follow-up. Consistent surveillance. Early detection. Cancer development. Prompt treatment.

Q3: How accurate is genetic testing for BRCA mutations?

Very accurate. DNA sequencing. Gold standard. 99+ percent sensitive and specific. For known mutations. Can miss. Large deletions. Complex rearrangements. Intronic mutations. Some mutations not detected. Negative test. Does not exclude. Small chance. Undetected mutation. 5 to 10 percent. Adequate for clinical management. Confirmatory testing. If unclear. Different methodology. Genetic counselor. Discusses test accuracy. Discusses interpretation.

Q4: Should I get tested if no family history of BRCA-related cancer?

Most people. No testing needed. General population risk. Low. No family history. Risk even lower. However. If. Multiple family members with breast or ovarian cancer. Ethnic background. Ashkenazi Jewish. Consider testing. Ancestry testing. Panethnic panels. Increase detection. Ashkenazi and other populations. Discuss with healthcare provider. Risk assessment. Determine if testing appropriate.

Q5: Can I do anything to prevent BRCA-related cancer?

No prevention. Complete. Cancer completely prevented. However. Risk reduction. Significant. Surveillance. Early detection. Dramatic impact. Cancer stage. Prognosis. Survival. Preventive medications. Reduce cancer risk. 30 to 50 percent. Preventive surgery. Mastectomy. Oophorectomy. Near-complete risk reduction. Lifestyle factors. Alcohol. Obesity. Exercise. Diet. Smoking. May influence risk. Modest. Comprehensive management. Multiple strategies. Reduce cancer incidence and mortality. Significantly.

Key Takeaways

BRCA1 and BRCA2 mutations are tumor suppressor gene variants. Dramatic cancer risk increase. Autosomal dominant inheritance. 50 percent offspring risk. BRCA1—45 to 87 percent breast cancer lifetime risk. 25 to 50 percent ovarian cancer lifetime risk. BRCA2—45 to 84 percent breast cancer risk. 10 to 25 percent ovarian cancer risk. Other cancers. Prostate. Pancreatic. Colorectal. Bile duct. Additional cancers. Approximately 5 to 10 percent breast cancers. Hereditary. Approximately 10 to 15 percent ovarian cancers. Hereditary. Who should test. Personal history breast cancer before age 50. Ovarian cancer any age. Male breast cancer. Jewish ancestry with cancer. Family history multiple cancers. Multiple relatives affected. Early-onset. Genetic counseling. Before and after testing. Important. Results interpretation. Pathogenic mutation—cancer risk increase. Genetic counseling. Medical management discussion. Benign variant—no increased risk. VUS—uncertain. Wait further research. Negative—population risk. But possibility of undetected mutation. Medical management. Enhanced surveillance. Mammography. MRI. Transvaginal ultrasound. PSA. Clinical breast examination. Preventive medications. Tamoxifen. Aromatase inhibitors. Reduce breast cancer risk. Preventive surgery. Mastectomy. 90 to 95 percent breast cancer risk reduction. Oophorectomy. 95 to 100 percent ovarian cancer risk reduction. 50 percent breast cancer risk reduction. Genetic testing. Family members. At-risk. Carrier identification. Early intervention. Psychological support. Counseling. Mental health. Support groups. Lifestyle factors. Alcohol. Obesity. Exercise. Diet. Smoking. May influence risk. Outcomes. Cancer risk—high. Risk reduction—possible. Surveillance—early detection. Survival—improved. Prevention—significant risk reduction. Quality of life—maintained. Informed decision-making—essential.

References

1. World Health Organization (WHO). “BRCA Mutations and Hereditary Breast and Ovarian Cancer.” Retrieved from https://www.who.int/
2. National Cancer Institute. “BRCA1 and BRCA2: Cancer Risk and Genetic Testing.” Retrieved from https://www.cancer.gov/
3. American Cancer Society. “Hereditary Cancer and BRCA Genes.” Retrieved from https://www.cancer.org/
4. Mayo Clinic. “BRCA Gene Test: What to Know.” Retrieved from https://www.mayoclinic.org/
5. Cleveland Clinic. “BRCA Mutations and Genetic Testing.” Retrieved from https://my.clevelandclinic.org/
6. National Comprehensive Cancer Network (NCCN). “Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic.” Retrieved from https://www.nccn.org/

Related Articles on ObserverVoice.com

Explore more health and science topics on our platform:

• Cancer Predisposition: Understanding Hereditary Cancer Syndromes
• Genetic Testing: Understanding DNA Screening for Disease Risk
• Breast Cancer: Understanding Risk Factors and Prevention
• Ovarian Cancer: Understanding Risk and Early Detection
• Genetic Counseling: Understanding Risk Assessment and Decision-Making
• Cancer Prevention: Understanding Surveillance and Risk Reduction Strategies

Disclaimer

This article adapts publicly available information from WHO sources. This content is for informational and educational purposes only and does not constitute medical advice. [ObserverVoice.com] is a news and information platform — not a healthcare provider. If you have personal or family history suggesting hereditary cancer risk—multiple family members with breast or ovarian cancer, cancer diagnosed young, Jewish ancestry—consult a qualified genetic counselor or oncologist for risk assessment. Genetic testing requires informed consent and professional guidance. Genetic counselor discusses risks, benefits, and implications before testing. Test results require professional interpretation. Genetic counselor discusses what results mean. Discusses medical management options. Discusses prevention strategies. Multiple management approaches available. Surveillance. Early detection. Preventive medications. Preventive surgery. Individual decision. Based on personal values. Risk tolerance. Life circumstances. Healthcare provider works with patient. Develops individualized plan. Cancer risk is serious. Risk reduction is possible. Early detection improves survival. With appropriate management, people at genetic risk can reduce cancer incidence and mortality significantly. Always seek guidance from licensed healthcare specialists and genetic counselors for testing, interpretation, and medical management.

Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.

Follow Us on Twitter, Instagram, Facebook, & LinkedIn